Advertisement

Rapid Spreading and Immune Evasion by Vaccinia Virus

  • Geoffrey L. SmithEmail author
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 808)

Abstract

Vaccinia virus (VACV) is the live vaccine that was used to eradicate smallpox, a feat achieved in 1977 and certified by the World Health Organization in 1980. Since 1980, research with VACV has continued in part because of the development of techniques to genetically manipulate VACV and create live VACV strains expressing foreign genes. These recombinant VACVs can be used as live vaccines against other infectious diseases and cancers, and as a powerful tool to study virus pathogenesis, immunology, cell biology, and virus–host interactions. This short article describes two examples of how enduring interest in VACV has revealed new features of VACV biology and the immune system.

Keywords

Vaccinia virus Smallpox vaccine Immune evasion Virus spreading mechanism 

Notes

Acknowledgments

Work in my laboratory has been supported generously by grants from the UK Medical Research Council and the Wellcome Trust, and I thank these funding agencies most warmly for this support. GLS is a Wellcome Trust Principal Research Fellow. I am also deeply grateful to the Nepalese Association of Medical Microbiology for the kind invitation to visit Nepal and speak at this First International Conference on Infectious Diseases and Nanomedicine-2012 (ICIDN-2012). On a personal note, it was a special honor to visit the country of the Gurkhas who were comrades in arms with my grandfather Professor Sir Ralph L Turner MC during the Great War and who saved his life in 1917, in Palestine. In the preface to R.L. Turner’s dictionary of the Nepali language [59] he expressed his lifelong respect and affection for the Gurkha soldier by words that are now engraved on the British Memorial to the Gurkha soldier in Whitehall, London and were unveiled by Her Majesty Queen Elizabeth II in 1997: “Bravest of the brave, most generous of the generous, never had country more faithful friends than you”. To be able to recite these words before the people and President of Nepal was an unforgettable experience.

References

  1. 1.
    Jenner E (1798) An enquiry into the causes and effects of variolae vaccinae, a disease discovered in some Western Countries of England, particularly Gloucestershire, and known by the name of cowpox. Cassell, London Reprinted by Cassell, 1896Google Scholar
  2. 2.
    Jenner E (1801) The origin of the vaccine inoculation. D.N. Shury, LondonGoogle Scholar
  3. 3.
    Fenner F, Anderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Smallpox and its eradication. World Health Organisation, GenevaGoogle Scholar
  4. 4.
    Baxby D (1981) Jenner’s smallpox vaccine: the riddle of the origin of vaccinia virus. Heinemann, LondonGoogle Scholar
  5. 5.
    Downie AW (1939) Immunological relationship of the virus of spontaneous cowpox to vaccinia virus. Br J Exp Pathol 20:158–176Google Scholar
  6. 6.
    Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79:4927–4931CrossRefGoogle Scholar
  7. 7.
    Mackett M, Smith GL, Moss B (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79:7415–7419CrossRefGoogle Scholar
  8. 8.
    Smith GL, Mackett M, Moss B (1983) Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302:490–495CrossRefGoogle Scholar
  9. 9.
    Smith GL, Murphy BR, Moss B (1983) Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA 80:7155–7159CrossRefGoogle Scholar
  10. 10.
    Panicali D, Davis SW, Weinberg RL, Paoletti E (1983) Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci USA 80:5364–5368CrossRefGoogle Scholar
  11. 11.
    Bennink JR, Yewdell JW, Smith GL, Moss B (1986) Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol 57:786–791Google Scholar
  12. 12.
    Osman M, Kubo T, Gill J, Neipel F, Becker M et al (1999) Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 73:6136–6140Google Scholar
  13. 13.
    Yewdell JW, Bennink JR, Smith GL, Moss B (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82:1785–1789CrossRefGoogle Scholar
  14. 14.
    Mackett M, Smith GL (1986) Vaccinia virus expression vectors. J Gen Virol 67:2067–2082CrossRefGoogle Scholar
  15. 15.
    Lane JM, Ruben FL, Neff JM, Millar JD (1969) Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med 281:1201–1208CrossRefGoogle Scholar
  16. 16.
    Roberts KL, Smith GL (2008) Vaccinia virus morphogenesis and dissemination. Trends Microbiol 16:472–479CrossRefGoogle Scholar
  17. 17.
    Smith GL, Vanderplasschen A, Law M (2002) The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83:2915–2931Google Scholar
  18. 18.
    Condit RC, Moussatche N, Traktman P (2006) In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res 66:31–124CrossRefGoogle Scholar
  19. 19.
    Hollinshead M, Vanderplasschen A, Smith GL, Vaux DJ (1999) Vaccinia virus intracellular mature virions contain only one lipid membrane. J Virol 73:1503–1517Google Scholar
  20. 20.
    Dales S, Siminovitch L (1961) The development of vaccinia virus in Earle’s L strain cells as examined by electron microscopy. J Biophys Biochem Cytol 10:475–503CrossRefGoogle Scholar
  21. 21.
    Sanderson CM, Hollinshead M, Smith GL (2000) The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J Gen Virol 81:47–58Google Scholar
  22. 22.
    Schmelz M, Sodeik B, Ericsson M, Wolffe EJ, Shida H et al (1994) Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 68:130–147Google Scholar
  23. 23.
    Tooze J, Hollinshead M, Reis B, Radsak K, Kern H (1993) Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur J Cell Biol 60:163–178Google Scholar
  24. 24.
    Hollinshead M, Rodger G, Van Eijl H, Law M, Hollinshead R et al (2001) Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol 154:389–402CrossRefGoogle Scholar
  25. 25.
    Ward BM, Moss B (2001) Vaccinia virus intracellular movement is associated with microtubules and independent of actin tails. J Virol 75:11651–11663CrossRefGoogle Scholar
  26. 26.
    Rietdorf J, Ploubidou A, Reckmann I, Holmstrom A, Frischknecht F et al (2001) Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat Cell Biol 3:992–1000CrossRefGoogle Scholar
  27. 27.
    Geada MM, Galindo I, Lorenzo MM, Perdiguero B, Blasco R (2001) Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein. J Gen Virol 82:2747–2760Google Scholar
  28. 28.
    Cudmore S, Cossart P, Griffiths G, Way M (1995) Actin-based motility of vaccinia virus. Nature 378:636–638CrossRefGoogle Scholar
  29. 29.
    Stokes GV (1976) High-voltage electron microscope study of the release of vaccinia virus from whole cells. J Virol 18:636–643Google Scholar
  30. 30.
    Hiller G, Weber K, Schneider L, Parajsz C, Jungwirth C (1979) Interaction of assembled progeny pox viruses with the cellular cytoskeleton. Virology 98:142–153CrossRefGoogle Scholar
  31. 31.
    Blasco R, Cole NB, Moss B (1991) Sequence analysis, expression, and deletion of a vaccinia virus gene encoding a homolog of profilin, a eukaryotic actin-binding protein. J Virol 65:4598–4608Google Scholar
  32. 32.
    Payne LG (1980) Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol 50:89–100CrossRefGoogle Scholar
  33. 33.
    Appleyard G, Hapel AJ, Boulter EA (1971) An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol 13:9–17CrossRefGoogle Scholar
  34. 34.
    Law M, Hollinshead R, Smith GL (2002) Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J Gen Virol 83:209–222Google Scholar
  35. 35.
    Payne LG (1979) Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. J Virol 31:147–155Google Scholar
  36. 36.
    Dulbecco R (1952) Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci USA 38:747–752CrossRefGoogle Scholar
  37. 37.
    Doceul V, Hollinshead M, van der Linden L, Smith GL (2010) Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327:873–876CrossRefGoogle Scholar
  38. 38.
    Carter GC, Rodger G, Murphy BJ, Law M, Krauss O et al (2003) Vaccinia virus cores are transported on microtubules. J Gen Virol 84:2443–2458CrossRefGoogle Scholar
  39. 39.
    Engelstad M, Howard ST, Smith GL (1992) A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188:801–810CrossRefGoogle Scholar
  40. 40.
    Parkinson JE, Smith GL (1994) Vaccinia virus gene A36R encodes a M(r) 43–50 K protein on the surface of extracellular enveloped virus. Virology 204:376–390CrossRefGoogle Scholar
  41. 41.
    Roper RL, Wolffe EJ, Weisberg A, Moss B (1998) The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J Virol 72:4192–4204Google Scholar
  42. 42.
    Lorenzo MM, Galindo I, Griffiths G, Blasco R (2000) Intracellular localization of vaccinia virus extracellular enveloped virus envelope proteins individually expressed using a Semliki Forest virus replicon. J Virol 74:10535–10550CrossRefGoogle Scholar
  43. 43.
    Roper RL, Payne LG, Moss B (1996) Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol 70:3753–3762Google Scholar
  44. 44.
    Rottger S, Frischknecht F, Reckmann I, Smith GL, Way M (1999) Interactions between vaccinia virus IEV membrane proteins and their roles in IEV assembly and actin tail formation. J Virol 73:2863–2875Google Scholar
  45. 45.
    Sanderson CM, Frischknecht F, Way M, Hollinshead M, Smith GL (1998) Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell–cell fusion. J Gen Virol 79:1415–1425Google Scholar
  46. 46.
    van Eijl H, Hollinshead M, Smith GL (2000) The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles. Virology 271:26–36CrossRefGoogle Scholar
  47. 47.
    Wolffe EJ, Weisberg AS, Moss B (2001) The vaccinia virus A33R protein provides a chaperone function for viral membrane localization and tyrosine phosphorylation of the A36R protein. J Virol 75:303–310CrossRefGoogle Scholar
  48. 48.
    Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801CrossRefGoogle Scholar
  49. 49.
    Medzhitov R (2007) Recognition of microorganisms and activation of the immune response. Nature 449:819–826CrossRefGoogle Scholar
  50. 50.
    Paludan SR, Bowie AG (2013) Immune sensing of DNA. Immunity 38:855–869CrossRefGoogle Scholar
  51. 51.
    Moss B (2007) Poxviridae: the viruses and their replicaton. In: Knipe DM (ed) Fields virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 2905–2946Google Scholar
  52. 52.
    Fahy AS, Clark RH, Glyde EF, Smith GL (2008) Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol 89:2377–2387CrossRefGoogle Scholar
  53. 53.
    Peters NE, Ferguson BJ, Mazzon M, Fahy AS, Krysztofinska E et al (2013) A mechanism for the inhibition of DNA-PK-mediated DNA sensing by vaccinia virus. PLoS Pathog 9: e1003649 Google Scholar
  54. 54.
    Ferguson BJ, Mansur DS, Peters NE, Ren H, Smith GL (2012) DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. elife 1: e00047Google Scholar
  55. 55.
    Gloeckner CJ, Boldt K, Schumacher A, Roepman R, Ueffing M (2007) A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7:4228–4234CrossRefGoogle Scholar
  56. 56.
    Collis SJ, DeWeese TL, Jeggo PA, Parker AR (2005) The life and death of DNA-PK. Oncogene 24:949–961CrossRefGoogle Scholar
  57. 57.
    Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O (2006) Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 22:511–519CrossRefGoogle Scholar
  58. 58.
    Rivera-Calzada A, Spagnolo L, Pearl LH, Llorca O (2007) Structural model of full-length human Ku70-Ku80 heterodimer and its recognition of DNA and DNA-PKcs. EMBO Rep 8:56–62CrossRefGoogle Scholar
  59. 59.
    Turner RL (1931) A comparative and etymological dictionary of the Nepali language. Oxford University Press, OxfordGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  1. 1.Department of PathologyUniversity of CambridgeCambridgeUK

Personalised recommendations